(Reuters) - AstraZeneca said on Friday a drug it is developing with Daiichi Sankyo's to treat patients with a type of breast cancer met one of the ...
- AstraZeneca said on Friday a drug it is developing with Daiichi Sankyo's to treat patients with a type of breast cancer met one of the main goals in a late-stage study. (Reporting byCountering the culture war with education and empathy | SaltWire #TransRights #HalifaxProtest.
- AstraZeneca said on Friday a drug it is developing with Daiichi Sankyo's to treat patients with a type of breast cancer met one of the main goals in a late-stage study. (Reporting byCountering the culture war with education and empathy | SaltWire #TransRights #HalifaxProtestFrance Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
AstraZeneca and Daiichi's breast cancer drug meets goal in study(Reuters) - AstraZeneca said on Friday a drug it is developing with Daiichi Sankyo's to treat patients with a type of breast cancer met one of the ...
Lire la suite »
BOJ will end negative interest rates in 2024, most economists say: Reuters pollBy Kantaro Komiya TOKYO (Reuters) - The Bank of Japan will end its negative interest rate policy next year, the majority of economists said in a ...
Lire la suite »
Americans broadly support auto, Hollywood strikes -Reuters/Ipsos pollBy Andy Sullivan WASHINGTON (Reuters) - Americans broadly back striking workers in the auto industry and Hollywood, according to a two-day ...
Lire la suite »
Bank of Japan will end negative interest rates in 2024, most economists say: Reuters pollMarket News
Lire la suite »
Japan business mood likely improved slightly in BOJ tankan: Reuters pollBy Leika Kihara TOKYO (Reuters) - A closely watched central bank survey is likely to show Japan's business confidence improved slightly in the three ...
Lire la suite »
AstraZeneca refused to pay full bonus to US remote worker, lawsuit claimsAstraZeneca Pharmaceuticals LP has been sued in the U.S. by a former senior director who claims the drugmaker refused to pay her nearly $130,000 in promised bonuses and stock options because she worked from home full-time. Elmarie Bodes, who was AstraZeneca's senior director of business transformation until January, said in the lawsuit filed in South Carolina state court on Tuesday that she was owed a $124,000 performance bonus and $65,000 in stock options. Instead, AstraZeneca earlier this year cut her payout in half and refused to grant any stock options because she did not come into the office at least three days per week, according to the lawsuit.
Lire la suite »